Evidence & Pharmacology

This page is general educational information only and is not medical advice. It aims to help readers understand how scientific evidence about medicines is generated and weighed, so that claims encountered elsewhere can be assessed more critically. It does not assess any specific substance.

In health and medicine, the strength of the evidence behind a statement matters as much as the statement itself. A claim supported by large, well-designed human trials carries very different weight to a claim based on a single laboratory experiment. Learning to tell these apart is a valuable skill, particularly in fields where enthusiasm can run ahead of the data.

Before a new medicine can be approved, it usually progresses through a structured sequence of clinical trials. Each phase answers different questions and builds on the one before:

• Preclinical research — laboratory and animal studies conducted before any human testing. This stage explores basic biology and safety signals.
• Phase 1 — small studies, typically in healthy volunteers, focused primarily on safety and how the body processes the substance.
• Phase 2 — larger studies that begin to examine effects and continue to assess safety.
• Phase 3 — large, often multi-site trials designed to provide robust data, usually required before regulatory approval.
• Phase 4 — ongoing monitoring after a medicine is approved and in wider use, sometimes called post-market surveillance.

A substance in an early phase has, by definition, not yet been shown to be effective. Describing something as being "in clinical trials" is a statement about process, not about proven results. It is also worth knowing that many candidates that enter this pipeline do not complete it; a large proportion fail at some stage, often because they do not work as hoped or because safety concerns emerge.

The randomised controlled trial (RCT) is widely regarded as the most reliable way to test whether a medicine has a genuine effect. Several design features make RCTs powerful:

• Randomisation — participants are assigned to groups by chance, which helps ensure the groups are comparable and reduces selection bias.
• Control group — one group receives the intervention while another receives a comparison, often a placebo (an inactive substance), so that genuine effects can be distinguished from background changes.
• Blinding — participants (single-blind) and often the researchers too (double-blind) do not know who received which treatment, reducing bias in how outcomes are experienced and recorded.

These features exist to guard against the many ways humans can be misled — including the well-documented placebo response, in which people can report changes after receiving an inactive substance, and unconscious bias in how outcomes are interpreted. Without these safeguards, it is remarkably easy to mistake noise, expectation or the natural course of events for a real effect.

Researchers often picture evidence as a hierarchy, with more rigorous study designs near the top:

• Systematic reviews and meta-analyses — structured syntheses that combine and appraise multiple studies using a defined method.
• Randomised controlled trials — well-designed experiments in humans.
• Cohort and case-control studies — observational studies that follow groups but do not randomise, useful but more prone to confounding.
• Case reports and expert opinion — useful for generating ideas but weak as proof.
• Laboratory and animal studies — important for understanding mechanisms but several steps removed from human outcomes.

No single study is ever the final word. Confidence grows when multiple high-quality studies, ideally using different methods and conducted by independent groups, point in the same direction. A well-conducted systematic review is valued precisely because it steps back and weighs the whole body of evidence rather than resting on any one result. It is also worth knowing that a single striking study, especially a small or early one, sometimes fails to hold up when others try to repeat it — a pattern common enough that scientists have a name for it, the replication problem. This is another reason that independent confirmation, rather than novelty, is what tends to build genuine confidence in a finding.

One of the most common errors in popular health writing is treating promising laboratory or animal findings as if they applied directly to people. They do not. The path from a hopeful test-tube result to a proven human treatment is long, and most candidates fail somewhere along the way.

A compound that shows an effect in cells in a dish is operating in a highly artificial environment, often at concentrations that could never be reached safely in a human body. Animal models are closer to human biology but still differ in important respects, and a result in one species does not guarantee the same result in another. History offers many examples of compounds that looked impressive in early research yet showed no benefit, or unacceptable harm, once tested rigorously in people. This is why careful sources say a substance is being studied for a question rather than implying the question is answered.

The same caution applies to mechanism claims. It is common to read that a substance "acts on" a particular receptor or pathway, and that this explains some hoped-for outcome. Knowing a plausible mechanism is genuinely useful for designing research, but a mechanism is a hypothesis about how something might work, not proof that it does. Biology is full of plausible mechanisms that turn out, when tested, to make no measurable difference in people.

Beyond study design, a handful of statistical ideas help in interpreting what a study actually shows:

• Statistical significance — a measure of how likely a result could have arisen by chance. It tells you something about confidence in a finding, but not about how large or meaningful the effect is.
• Effect size — how big the observed difference is. A result can be statistically significant yet so small that it carries little practical importance.
• Confidence intervals — a range that expresses the uncertainty around an estimate. Wide intervals signal greater uncertainty.
• Sample size — larger, well-designed studies generally provide more reliable estimates than small ones.

Popular reporting often collapses these distinctions, presenting any "significant" result as a breakthrough. Holding these concepts in mind helps you read past headlines and ask what a study genuinely demonstrates. None of this requires advanced mathematics — just an awareness that the strength of a claim depends on more than whether a study found something.

Some practical warning signs can help you gauge the strength of a claim:

• The evidence comes only from laboratory or animal studies.
• Studies are very small, lack a control group, or are not blinded.
• Results are described in dramatic or absolute language rather than with appropriate caution.
• A single study is presented as if it settled the matter.
• Findings are reported only by parties with a commercial interest and have not been independently replicated.
• Anecdotes or testimonials are offered in place of systematic data.

The term investigational is important here. When a substance is described as investigational, it means it is still being studied and has not been established as a proven, approved treatment for the use in question. The word is sometimes used loosely in marketing to lend an air of scientific credibility, so it is worth reading carefully: "under investigation" is a statement about ongoing study, not a conclusion. Recognising this language helps set realistic expectations and helps separate what is genuinely known from what is merely hoped. As always, this page is general information only — for guidance about your own health, consult a qualified health practitioner who can interpret the current evidence in light of your circumstances.